In the TME of breast cancer, myCAFs were shown to promote an immunosuppressive environment by attracting and retaining CD4+CD25+ T-cells through the ligands tumor necrosis factor receptor superfamily member 4 (OX40L), PD-L2, and the adhesion molecule junctional adhesion molecule B (JAM2). Here, JAM2 is linked to breast carcinoma.